Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foral, P. A.
Right arrow Articles by Hilleman, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foral, P. A.
Right arrow Articles by Hilleman, D. E.
(Chest. 2004;125:691-694.)
© 2004 American College of Chest Physicians

Nebulized Opioids Use in COPD*

Pamela A. Foral, PharmD, BCPS; Mark A. Malesker, PharmD; Guillermo Huerta, MD, FCCP and Daniel E. Hilleman, PharmD

* From Creighton University School of Pharmacy and Health Professions (Drs. Foral, Malesker, and Hilleman), Omaha; and Creighton University School of Medicine, Omaha, NE.

Correspondence to: Pamela A. Foral, PharmD, BCPS, Creighton University School of Pharmacy and Health Professions, 2500 California Plaza, Omaha, NE 68178; e-mail: pforal{at}creighton.edu

Objective: To evaluate the role of nebulized opioids in COPD.

Methods: A MEDLINE search was completed to obtain pertinent clinical literature. Key search terms included the following: nebulizer, opioids, COPD, dyspnea, morphine, and hydromorphone.

Results: Currently, the evidence in the literature is lacking regarding placebo-controlled studies to support nebulized morphine for the relief of dyspnea in patients with COPD. The studies reviewed varied considerably in the dose, opioid used, administration schedule, and methodology. One study found improved exercise capacity in 11 patients not reproducible in a larger sample, and another study found benefit in 54 terminal patients. All other studies found no benefit.

Conclusions: The recently published Global Initiative for Lung Disease guidelines have specifically stated that opioids are contraindicated in COPD management due to the potential respiratory depression and worsening hypercapnia. Nebulized opioids should be discouraged, as current data do not support their use.

Key Words: COPD • dyspnea • nebulizer • opioids




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. B. Shirk, K. R. Donahue, and J. Shirvani
Unlabeled uses of nebulized medications.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. J Brown, S. F Eichner, and J. R Jones
Nebulized Morphine for Relief of Dyspnea Due to Chronic Lung Disease
Ann. Pharmacother., June 1, 2005; 39(6): 1088 - 1092.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.